A review of renal disease in cystic fibrosis

Journal of Cystic Fibrosis

Volumn 12, Issue 4, 2013, Pages 309-317

  Nazareth, Dilip ^a   Walshaw, Martin ^a  

^a LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

Author keywords

Aminoglycosides; Creatinine clearance; Fosfomycin; Measurement of renal function; Renal disease

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFTAZIDIME; COLISTIN; FOSFOMYCIN; GENTAMICIN; TOBRAMYCIN;

ACUTE KIDNEY FAILURE; AMYLOIDOSIS; ANTIBIOTIC THERAPY; COMPETITIVE INHIBITION; CYSTIC FIBROSIS; DIABETES MELLITUS; DOSAGE SCHEDULE COMPARISON; DRUG MEGADOSE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY DYSFUNCTION; MORBIDITY; NEPHROLITHIASIS; NEPHROTOXICITY; PATHOPHYSIOLOGY; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW; SCREENING;

EID: 84878353835     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2013.03.005     Document Type: Review

References (89)

1. Jouret F., Bernard A., Hermans C., Dom G., Terryn S., Leal T., et al. Cystic fibrosis is associated with a defect in apical receptor-mediated endocytosis in mouse and human kidney. J Am Soc Nephrol 2007, 18:707-718.
2. Bertram J.F., Douglas-Denton R.N., Diouf B., Hughson M.D., Hoy W.E. Human nephron number: implications for health and disease. Pediatr Nephrol 2011, 26:1529-1533.
3. Ballestero Y., Hernandez M.I., Rojo P., Manzanares J., Nebreda V., Carbajosa H., et al. Hyponatremic dehydration as a presentation of cystic fibrosis. Pediatr Emerg Care 2006, 22:725-727.
4. Cystic Fibrosis Foundation Patient Registry Annual data report 2010 2011, Cystic Fibrosis Foundation.
5. Quon B.S., Mayer-Hamblett N., Aitken M.L., Smyth A.R., Goss C.H. Risk factors for chronic kidney disease in adults with cystic fibrosis. Am J Respir Crit Care Med 2011, 184:1147-1152.
6. Levey A.S. Measurement of renal function in chronic renal disease. Kidney Int 1990, 38:167-184.
7. Rahn K.H., Heidenreich S., Bruckner D. How to assess glomerular function and damage in humans. J Hypertens 1999, 17:309-317.
8. Anderson S., Rennke H.G., Brenner B.M. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986, 77:1993-2000.
9. Hostetter T.H., Olson J.L., Rennke H.G., Venkatachalam M.A., Brenner B.M. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981, 241:F85-F93.
10. Rule A.D., Larson T.S., Bergstralh E.J., Slezak J.M., Jacobsen S.J., Cosio F.G. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 2004, 141:929-937.
11. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
12. Tan K.H., Mulheran M., Knox A.J., Smyth A.R. Aminoglycoside prescribing and surveillance in cystic fibrosis. Am J Respir Crit Care Med 2003, 167:819-823.
13. Thakur V., Reisin E., Solomonow M., Baratta R., Aguilar E., Best R., et al. Accuracy of formula-derived creatinine clearance in paraplegic subjects. Clin Nephrol 1997, 47:237-242.
14. Guasch A., Cua M., Mitch W.E. Early detection and the course of glomerular injury in patients with sickle cell anemia. Kidney Int 1996, 49:786-791.
15. Vinton N.E., Padman R., Davis M., Harcke H.T. Effects of Pseudomonas colonization on body composition and resting energy expenditure in children with cystic fibrosis. JPEN J Parenter Enteral Nutr 1999, 23:233-236.
16. Selvadurai H.C., Allen J., Sachinwalla T., Macauley J., Blimkie C.J., Van Asperen P.P. Muscle function and resting energy expenditure in female athletes with cystic fibrosis. Am J Respir Crit Care Med 2003, 168:1476-1480.
17. Al-Aloul M., Jackson M., Bell G., Ledson M., Walshaw M. Comparison of methods of assessment of renal function in cystic fibrosis (CF) patients. J Cyst Fibros 2007, 6:41-47.
18. Sethi K., Diamond L.H. Aminoglycoside nephrotoxicity and its predictability. Nephron 1981, 27:265-270.
19. Mondorf A.W. Urinary enzymes. Characterization and diagnostic use. MMW Munch Med Wochenschr 1982, 124:230.
20. Trollfors B., Wahl M., Alestig K. Co-trimoxazole, creatinine and renal function. J Infect 1980, 2:221-226.
21. Steinkamp G., Lutge M., Wurster U., Schulz-Baldes J.G., Grone H.J., Ehrich J.H. Renal function in cystic fibrosis: proteinuria and enzymuria before and after tobramycin therapy. Eur J Pediatr 1986, 145:526-531.
22. Etherington C., Bosomworth M., Clifton I., Peckham D.G., Conway S.P. Measurement of urinary N-acetyl-b-d-glucosaminidase in adult patients with cystic fibrosis: before, during and after treatment with intravenous antibiotics. J Cyst Fibros 2007, 6:67-73.
23. Devarajan P. Emerging biomarkers of acute kidney injury. Contrib Nephrol 2007, 156:203-212.
24. Han W.K., Bailly V., Abichandani R., Thadhani R., Bonventre J.V. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002, 62:237-244.
25. Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease. Scand J Clin Lab Invest Suppl 2008, 241:89-94.
26. Lim A.I., Tang S.C., Lai K.N., Leung J.C. Kidney injury molecule-1: more than just an injury marker of tubular epithelial cells?. J Cell Physiol 2013, 228:917-924.
27. Newman D.J., Cystatin C. Ann Clin Biochem 2002, 39:89-104.
28. Beringer P.M., Hidayat L., Heed A., Zheng L., Owens H., Benitez D., et al. GFR estimates using cystatin C are superior to serum creatinine in adult patients with cystic fibrosis. J Cyst Fibros 2009, 8:19-25.
29. Halacova M., Kotaska K., Kukacka J., Vavrova V., Kuzelova M., Ticha J., et al. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin. J Clin Pharm Ther 2008, 33:409-417.
30. Soulsby N., Greville H., Coulthard K., Doecke C. What is the best method for measuring renal function in adults and children with cystic fibrosis?. J Cyst Fibros 2010, 9:124-129.
31. de Groot R., Smith A.L. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance. Clin Pharmacokinet 1987, 13:228-253.
32. Mingeot-Leclercq M.P., Glupczynski Y., Tulkens P.M. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother 1999, 43:727-737.
33. Pannu N., Nadim M.K. An overview of drug-induced acute kidney injury. Crit Care Med 2008, 36:S216-S223.
34. Samaniego-Picota M.D., Whelton A. Aminoglycoside-induced nephrotoxicity in cystic fibrosis: a case presentation and review of the literature. Am J Ther 1996, 3:248-257.
35. Al-Aloul M., Miller H., Alapati S., Stockton P.A., Ledson M.J., Walshaw M.J. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 2005, 39:15-20.
36. Jain K., Prayle A., Lewis S., Watson A., Knox A., Dewar J., et al. Assessment of renal function in cystic fibrosis patients by estimated and measured glomerular filtration rate - a cross-sectional study. J Cyst Fibros 2012, 11:S52.
37. Ciofu O., Giwercman B., Pedersen S.S., Hoiby N. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center. APMIS 1994, 102:674-680.
38. Breen L., Aswani N. Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis. Cochrane Database Syst Rev 2012, 7:CD002767.
39. Elborn J.S., Prescott R.J., Stack B.H., Goodchild M.C., Bates J., Pantin C., et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax 2000, 55:355-358.
40. Prayle A., Watson A., Fortnum H., Smyth A. Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis. Thorax 2010, 65:654-658.
41. Adeboyeku D., Jones A.L., Hodson M.E. Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis. J Cyst Fibros 2011, 10:25-30.
42. Riethmueller J., Ballmann M., Schroeter T.W., Franke P., von Butler R., Claass A., et al. Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients. Infection 2009, 37:424-431.
43. Smyth A., Tan K.H., Hyman-Taylor P., Mulheran M., Lewis S., Stableforth D., et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - the TOPIC study: a randomised controlled trial. Lancet 2005, 365:573-578.
44. Vic P., Ategbo S., Turck D., Husson M.O., Launay V., Loeuille G.A., et al. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for Pseudomonas exacerbations in cystic fibrosis. Arch Dis Child 1998, 78:536-539.
45. Massie J., Cranswick N. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis. J Paediatr Child Health 2006, 42:601-605.
46. Flume P.A., Robinson K.A., O'Sullivan B.P., Finder J.D., Vender R.L., Willey-Courand D.B., et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care 2009, 54:522-537.
47. Antibiotic treatment for Cystic Fibrosis Report of the UK Cystic Fibrosis Trust Antibiotic Working Group 2009, 3rd ed.
48. Vic P., Ategbo S., Turck D., Husson M.O., Launay V., Loeuille G.A., et al. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis. Arch Dis Child Educ Pract Ed 1998, 78(6):536-539.
49. Al-Aloul M., Miller H., Browning P., Ledson M.J., Walshaw M.J. A randomised cross over trial of TOBI vs IV tobramycin in acute pulmonary exacerbations in CF. Pediatr Pulmonol 2004, 38:P179.
50. Hoffmann I.M., Rubin B.K., Iskandar S.S., Schechter M.S., Nagaraj S.K., Bitzan M.M. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Pediatr Pulmonol 2002, 34:375-377.
51. Florescu M.C., Lyden E., Murphy P.J., Florescu D.F., Fillaus J. Long-term effect of chronic intravenous and inhaled nephrotoxic antibiotic treatment on the renal function of patients with cystic fibrosis. Hemodial Int 2012, 16:414-419.
52. Hendlin D., Stapley E.O., Jackson M., Wallick H., Miller A.K., Wolf F.J., et al. Phosphonomycin, a new antibiotic produced by strains of Streptomyces. Science 1969, 166:122-123.
53. Katznelson D., Yahav Y., Rubinstein E. Fosfomycin in the treatment of cystic fibrosis. Eur J Clin Microbiol 1984, 3:213.
54. Farago E., Kiss I.J., Nabradi Z. Serum and lung tissue levels of fosfomycin in humans. Int J Clin Pharmacol Ther Toxicol 1980, 18:554-558.
55. Mirakhur A., Gallagher M.J., Ledson M.J., Hart C.A., Walshaw M.J. Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis. J Cyst Fibros 2003, 2:19-24.
56. Al-Aloul M., Ledson M., Walshaw M.J. Renoprotective effect of fosfomycin in the treatment of multiresistant Pseudomonas aeruginosa in CF. Thorax 2004, 59:P121.
57. Bertenshaw C., Watson A.R., Lewis S., Smyth A. Survey of acute renal failure in patients with cystic fibrosis in the UK. Thorax 2007, 62:541-545.
58. Izquierdo M.J., Gomez-Alamillo C., Ortiz F., Calabia E.R., Ruiz J.C., de Francisco A.L., et al. Acute renal failure associated with use of inhaled tobramycin for treatment of chronic airway colonization with Pseudomonas aeruginosa. Clin Nephrol 2006, 66:464-467.
59. Al-Aloul M., Miller H., Stockton P., Ledson M.J., Walshaw M.J. Acute renal failure in CF patients chronically infected by the Liverpool epidemic Pseudomonas aeruginosa strain (LES). J Cyst Fibros 2005, 4:197-201.
60. Edson R.S., Terrell C.L. The aminoglycosides. Mayo Clin Proc 1999, 74:519-528.
61. Christie J.D., Edwards L.B., Kucheryavaya A.Y., Aurora P., Dobbels F., Kirk R., et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report - 2010. J Heart Lung Transplant 2010, 29:1104-1118.
62. Ruggenenti P., Perico N., Mosconi L., Gaspari F., Benigni A., Amuchastegui C.S., et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993, 43:706-711.
63. Lamas S. Cellular mechanisms of vascular injury mediated by calcineurin inhibitors. Kidney Int 2005, 68:898-907.
64. Lanese D.M., Conger J.D. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 1993, 91:2144-2149.
65. Bloom R.D., Reese P.P. Chronic kidney disease after nonrenal solid-organ transplantation. J Am Soc Nephrol 2007, 18:3031-3041.
66. Wilkinson A.H., Cohen D.J. Renal failure in the recipients of nonrenal solid organ transplants. J Am Soc Nephrol 1999, 10:1136-1144.
67. Lefaucheur C., Nochy D., Amrein C., Chevalier P., Guillemain R., Cherif M., et al. Renal histopathological lesions after lung transplantation in patients with cystic fibrosis. Am J Transplant 2008, 8:1901-1910.
68. Quon B.S., Mayer-Hamblett N., Aitken M.L., Goss C.H. Risk of post-lung transplant renal dysfunction in adults with cystic fibrosis. Chest 2012, 142:185-191.
69. Ojo A.O., Held P.J., Port F.K., Wolfe R.A., Leichtman A.B., Young E.W., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003, 349:931-940.
70. Katz S.M., Krueger L.J., Falkner B. Microscopic nephrocalcinosis in cystic fibrosis. N Engl J Med 1988, 319:263-266.
71. Chidekel A.S., Dolan T.F. Cystic fibrosis and calcium oxalate nephrolithiasis. Yale J Biol Med 1996, 69:317-321.
72. Hoppe B., Hesse A., Bromme S., Rietschel E., Michalk D. Urinary excretion substances in patients with cystic fibrosis: risk of urolithiasis?. Pediatr Nephrol 1998, 12:275-279.
73. Perez-Brayfield M.R., Caplan D., Gatti J.M., Smith E.A., Kirsch A.J. Metabolic risk factors for stone formation in patients with cystic fibrosis. J Urol 2002, 167:480-484.
74. Strandvik B., Hjelte L. Nephrolithiasis in cystic fibrosis. Acta Paediatr 1993, 82:306-307.
75. Gibney E.M., Goldfarb D.S. The association of nephrolithiasis with cystic fibrosis. Am J Kidney Dis 2003, 42:1-11.
76. Mc Laughlin A.M., Crotty T.B., Egan J.J., Watson A.J., Gallagher C.G. Amyloidosis in cystic fibrosis: a case series. J Cyst Fibros 2006, 5:59-61.
77. McGlennen R.C., Burke B.A., Dehner L.P. Systemic amyloidosis complicating cystic fibrosis. A retrospective pathologic study. Arch Pathol Lab Med 1986, 110:879-884.
78. Kuwertz-Broking E., Koch H.G., Schulze Everding A., Bulla M., Dworinczak B., Helmchen U., et al. Colchicine for secondary nephropathic amyloidosis in cystic fibrosis. Lancet 1995, 345:1178-1179.
79. Davis C.A., Abramowsky C.R., Swinehart G. Circulating immune complexes and the nephropathy of cystic fibrosis. Hum Pathol 1984, 15:244-247.
80. Melzi M.L., Costantini D., Giani M., Appiani A.C., Giunta A.M. Severe nephropathy in three adolescents with cystic fibrosis. Arch Dis Child 1991, 66:1444-1447.
81. Stirati G., Antonelli M., Fofi C., Fierimonte S., Pecci G. IgA nephropathy in cystic fibrosis. J Nephrol 1999, 12:30-31.
82. Moran A., Dunitz J., Nathan B., Saeed A., Holme B., Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 2009, 32:1626-1631.
83. Koch C., Rainisio M., Madessani U., Harms H.K., Hodson M.E., Mastella G., et al. Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol 2001, 32:343-350.
84. Report of the UK Cystic Fibrosis Trust Diabetes Working Group: management of cystic fibrosis related diabetes mellitus 2004, Kent, U.K.
85. Moran A., Brunzell C., Cohen R.C., Katz M., Marshall B.C., Onady G., et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010, 33:2697-2708.
86. Hameed S., Morton J.R., Jaffe A., Field P.I., Belessis Y., Yoong T., et al. Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain. Diabetes Care 2010, 33:221-226.
87. Dyce P., Daniels J., Govin B., Malone V., Nazareth D., Walshaw M. Continuous glucose monitoring (CGM) for cystic fibrosis related diabetes (CFRD): sweet success or bitter disappointment?. Pediatr Pulmonol 2012, 47.
88. Dobson L., Stride A., Bingham C., Elworthy S., Sheldon C.D., Hattersley A.T. Microalbuminuria as a screening tool in cystic fibrosis-related diabetes. Pediatr Pulmonol 2005, 39:103-107.
89. van den Berg J.M., Morton A.M., Kok S.W., Pijl H., Conway S.P., Heijerman H.G. Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD). J Cyst Fibros 2008, 7:515-519.